AGLE Quote Trading Chart Aeglea BioTherapeutics Inc.

$0.4874 Last:

16.05% Change Percent:

$0.5 Open:

$0.42 Previous Close:

$0.516 High:

$0.4831 Low:

317,085 Volume:

12/31/1969 07:00:00 pm Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2022-08-15	0.5	0.42	0.516	0.4831	317,085
2022-08-12	0.4849	0.42	0.52	0.4624	445,518
2022-08-11	0.47	0.42	0.518	0.45	952,955
2022-08-10	0.42	0.42	0.4699	0.41	3,197,462
2022-08-09	0.42	0.42	0.45	0.401	287,192
2022-08-08	0.441	0.42	0.451	0.42	205,766
2022-08-05	0.43	0.42	0.43	0.4157	282,285
2022-08-04	0.41	0.42	0.42	0.395	276,951
2022-08-03	0.4029	0.42	0.4257	0.389	422,150
2022-08-02	0.395	0.42	0.3957	0.372	161,238
2022-08-01	0.41	0.42	0.41	0.39	200,924
2022-07-29	0.4158	0.42	0.4295	0.4	171,235
2022-07-28	0.42	0.42	0.43	0.4056	231,326
2022-07-26	0.4386	0.4386	0.4401	0.4	115,819
2022-07-25	0.4366	0.4094	0.4389	0.4094	99,656
2022-07-19	0.4647	0.4763	0.4864	0.4644	164,395
2022-07-18	0.4693	0.461	0.4799	0.4564	85,000
2022-07-15	0.47	0.4689	0.4822	0.46	249,754
2022-07-14	0.48	0.47	0.5022	0.4526	252,530
2022-07-13	0.483	0.4821	0.5076	0.48	533,386

Stock Information

Aeglea BioTherapeutics Inc. Company Name:

AGLE Stock Symbol:

NASDAQ Market:

Get AGLE Alerts

News, Short Squeeze, Breakout and More Instantly...

AGLE - Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates PR Newswire Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forwar...
AGLE - Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnol...
AGLE - Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market PR Newswire AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company ...